Genomics

19 May 2017

Horizon Discovery – Parkwalk UCEF I exit

By |May 19th, 2017|

We are delighted to have generated a 2.36x return (3.37x inclusive of initial tax reliefs) for our investors on the sale of the University of Cambridge Enterprise Fund I holding in Horizon Discovery plc. The investment was held for 3.9 years and the exit was generated through a single block trade.
We would like to thank […]

Predictimmune – Parkwalk closes investment

By |May 16th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund IV have completed an investment in Predictimmune Limited, a spinout company from the University of Cambridge.
Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes. Their first offering, PredictImmune-CD, will be […]

28 February 2017

Parkwalk closes PhoreMost follow-on investment

By |February 28th, 2017|

We are pleased to announce that Parkwalk has made an investment in Phoremost, a Cambridge University spinout, as part of a Series ‘B’ round of equity funding, alongside Amadeus Capital Partners and the University. Phoremost’s mission is to accelerate, diversify and rationalise drug discovery.

PhoreMost has developed a next-generation phenotypic screening platform called ‘SiteSeeker’ to identify […]

Congenica – Parkwalk closes investment

By |February 15th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund and the Parkwalk Technology Fund VII have invested in a $10m Series ‘B’ financing round for Congenica Limited, which spun out of the Wellcome Trust Sanger Institute and Department of Health. Congenica has developed software that enables the accurate, rapid and scalable clinical interpretation of […]

20 September 2016

Horizon Discovery – Strong Revenue Growth and Focus on Operational Gearing Underpin Path to Profitability

By |September 20th, 2016|

Cambridge, UK, 20 September 2016: Horizon Discovery Group plc (LSE: HZD), a world leader in the application of gene editing technologies, announces its interim results for the six months ended 30 June 2016.
Highlights (including post period end):
Financial
·     Group revenue increased 19% to £10.2 million (HY15: £8.6 million)
·     Products business revenue increased 62% to £4.8 […]

20 August 2015

Parkwalk closes Xerion investment

By |August 20th, 2015|

We are pleased to announce that the University of Oxford Isis Fund II has made an investment in Xerion, a nanoparticle company spun-out of the University with a novel treatment for cancer.

Xerion seeks to commercialise Dr Helen Townley’s Research Group’s work into the use of nanoparticles in cancer for therapy, imaging and drug delivery.
The small […]

Parkwalk closes Quethera investment

By |August 13th, 2015|

We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in Quethera, a gene therapy company spun-out of the University with a novel treatment for glaucoma.

Quethera announces seed financing to develop gene therapy aimed at preventing blindness in glaucoma patients

CAMBRIDGE, UK, 17th September 2015: Quethera, a gene therapy […]

1 May 2015

Horizon Discovery – Placing to raise approximately £25 million to accelerate the Company’s growth strategy

By |May 1st, 2015|

Horizon Discovery Group plc (LSE:HZD), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, is pleased to announce a conditional non-pre-emptive placing of 13,157,895 New Placing Shares at a Placing Price of 190 pence per share to raise approximately £25.0 million before expenses. […]

7 April 2015

Parkwalk closes PhoreMost investment

By |April 7th, 2015|

We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in PhoreMost as part of a £4m series ‘A’ round of equity and grant funding, of which the equity tranche was led by Amadeus Capital Partners and the Abcam founder, Jonathan Milner.

PhoreMost has developed a next-generation phenotypic […]

19 January 2015

Horizon Discovery – Positive Trading Update

By |January 19th, 2015|

Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering

Cambridge, UK – 19th January 2014: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the international life science company supplying research tools and services to organizations engaged in genomics research […]

29 September 2014

Horizon Discovery – acquires Sage Labs Inc. for $48M

By |September 29th, 2014|

Acquisition makes Horizon the world’s leading gene-editing and translational genomics company
Highlights
·     Horizon acquires Sage Labs Inc. for up to $48M (£29M) comprising up to $16M in cash and up to $32M in new ordinary shares
·     Acquisition creates a fully integrated and world leading translational genomics platform
·     Significantly expands Horizon’s product, service and research offerings providing cost consolidation, and […]

Horizon Discovery – Interim Results

By |September 23rd, 2014|

Interim Results in-line and Panmure reaffirms ‘Buy Rating’:

Interim Results for the Six Months Ended 30 June 2014

Horizon Reports a Strong First Half Positioning the Company for Continued Growth

Cambridge, UK, 23 September 2014: Horizon Discovery Group plc (LSE: HZD), the international life science company supplying research tools to organisations engaged in genomics research and the […]

20 June 2014

Horizon Discovery – wins European Mediscience’s Emerging Star Award 2014

By |June 20th, 2014|

Horizon Discovery Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, is delighted to announce that it has won the “Emerging Star” category at last night’s (Thursday’s) European Mediscience Awards in London.

Read more here.

16 April 2014

Horizon Discovery Says It Has Continued To Trade Strongly Since IPO

By |April 16th, 2014|

Horizon Discovery Group PLC said Wednesday that it had continued to trade strongly since its initial public offering.

The company said it had traded “at least in line with expectations”, and that it is pursuing its strategy to make acquisitions, expand its intellectual property portfolio, geographic footprint, sales and distribution channels.

24 March 2014

Horizon Discovery – Record AIM $113m IPO

By |March 24th, 2014|

Parkwalk portfolio company Horizon Discovery is set to create UK stock market history with a significantly oversubscribed AIM IPO on Thursday March 27, with a market cap of £120.5 million after raising £68.6m from institutional investors against an original target of £25m.
Read more here.

27 February 2014

Horizon – Intention to float on AIM

By |February 27th, 2014|

Horizon Discovery Group plc Announces Intention to Float 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE SAME […]

Horizon Discovery

By |February 8th, 2014|

Appointment of Chairman – Horizon Discovery has appointed Dr. Ian Gilham as Chairman of its Board of Directors.

Dr. Gilham’s healthcare industry career spans thirty years encompassing all aspects of successful company growth and development. He was Chief Executive Officer of Axis-Shield plc, prior to its sale to Alere and he has also held top management […]

30 January 2014

Horizon Discovery

By |January 30th, 2014|

Horizon Discovery Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan

Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines

Cambridge, UK, 30 January 2014: Horizon Discovery™ (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has entered into a […]

Horizon Discovery

By |January 7th, 2014|

Jan 7 (Reuters) – Horizon Discovery: * Horizon discovery and Astrazeneca have entered into a research, collaboration and license agreement * Agreement to explore a range of oncology-relevant genotypes * Will receive an undisclosed upfront payment * Eligible for subsequent payments of up to $88 mln in milestones if compounds are developed by Astrazeneca

13 November 2013

Horizon Discovery

By |November 13th, 2013|

Horizon Discovery named in the Deloitte Tech Fast 50 2013